Meeting
2024 ASCO Genitourinary Cancers Symposium
Impact of TP53, RB1, and PTEN mutations on overall survival in metastatic prostate cancer: A multi-center study via the Guardian Research Network.
Authors
Mohammad Arfat Ganiyani
Miami Cancer Institute, Baptist Health South Florida, Miami, FL
Mohammad Arfat Ganiyani , Pushan Prabhakar , Atulya Aman Khosla , Shreyas S Bellur , Arjun Pon Avudaiappan , Liz Bond , Suresh Marada , Andrea McCracken , Charlie Hurmiz , Bruno R. Bastos , Rohan Garje
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 82)
DOI
10.1200/JCO.2024.42.4_suppl.82
Abstract #
82
Poster Bd #
C17
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Genomic evolution from hormonal therapies and suitability of prostate cancer diagnostic specimens for metastatic prostate cancer (mPC) genomic stratification.
First Author: Amado J. Zurita
Poster
2023 ASCO Annual Meeting
The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.
First Author: Philip C. Mack
Poster
2022 ASCO Annual Meeting
Molecular alterations associated with rapid progression following CDK4/6 inhibitors (CDKi) in metastatic hormone receptor–positive breast cancer (mHRBC).
First Author: Malinda T West
First Author: Jie Lin